tradingkey.logo

BRIEF-Abivax Achieves Key Milestone In Phase 3 Abtect Trial Enrollment

ReutersJan 9, 2025 4:56 PM

- Abivax SA ABVX.PA:

  • ABIVAX ACHIEVES KEY MILESTONE IN PHASE 3 ABTECT TRIAL ENROLLMENT

  • TOP-LINE RESULTS FOR 8-WEEK INDUCTION TRIAL EXPECTED IN Q3 2025

  • ENROLLMENT COMPLETION EXPECTED IN Q2 2025

  • PHASE 3 ABTECT TRIAL REACHES 82% OF TARGET ENROLLMENT

Source text: nGNXb5Lpc9

Further company coverage: ABVX.PA

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Related Articles